An observational study in Type 1 Diabetes, sponsored by Hospital St. Joseph, Marseille, France. Completed at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-09.
Sponsored by Hospital St. Joseph, Marseille, France · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 271 studies in Diabetes Mellitus, Type 1 with a site in France — 40 open to participants now, 47 under way, 8 of them phase 3. Diabetes Mellitus, Type 1 · France.
Among the 271 studies in Diabetes Mellitus, Type 1 with a site in France, this one is the 29th largest by enrollment of the 78 observational ones that give a count, is one of 14 that started in 2022, is one of 78 observational ones, and was the 219th registered.
3,754 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →40 of the 271 studies in Diabetes Mellitus, Type 1 with a site in France are open now. Recruiting first, the newest first:
Insulet Corporation · Sites in France
Ages 2+
Sanofi · Sites in France, Belgium, Germany and 3 more countries
Tandem Diabetes Care, Inc. · Sites in France
Ages 6+
Eli Lilly and Company · Sites in France, United States, Australia and 17 more countries
Ages 1–35
Eli Lilly and Company · Sites in France, United States, Australia and 16 more countries
Ages 1–35
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
271 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 25 · Phase 3 55 · Phase 4 7
First in 2000; this study’s year is marked. 14 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 297 is above the median of 125 across 792 observational studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 67 across the 193 interventional studies, 153 across the 78 observational. Of the 202 that completed or were terminated, 48 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
90 of 271 have an industry lead sponsor. The 10 most frequent:
Hospital St. Joseph, Marseille, France is the lead sponsor of 31 studies on the registry; 4 are open to participants now.
Hospital St. Joseph, Marseille, France has 1 study filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
18 of the studies in Diabetes Mellitus, Type 1 with a site in France that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT04583462Phase 3Assistance Publique - Hôpitaux de ParisImpact of Metformin on Peripheral Arterial Calcification in Type 1 Diabetes | 2027-09-29 |
| NCT04598893Provention Bio, a Sanofi CompanyRecent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension) | 2026-11 |
| NCT07457580SanofiReal-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) | 2026-11-30 |
Add all 18 to your calendar (.ics) → With an account.
Among the 271 studies in Diabetes Mellitus, Type 1 with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In France, the adult population living with diabetes in 2016 is estimated at more than 3.3 million patients treated. Type 1 diabetes (T1DM) represents 5.6% of diabetic patients (approximately 185,000 patients).
Numerous studies show that patients fear hypoglycemia, with an impact on their quality of life, sleep disorders and depressive symptoms. In addition, there is a metabolic impact with a problem of therapeutic compliance and an alteration of glycemic control.
This study examine the relation between Post Traumatic Stress disorder (PTSD) and diabetes diagnosis or severe hypoglycaemia in adults with Type 1 Diabetes.
The aim of this study is to evaluate the prevalence of PTSD in this population.
population of insulin-treated type 1 diabetic patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
PCL-S and HADS questionnaires
Also known as: Diagnostic Test: HADS Questionnaire
To evaluate the prevalence of post-traumatic stress disorder (PTSD) in adult with Type 1 Diabetes
Score (\>44) measured on the Posttraumatic Stress Disorder Checklist Scale (PCL-S) for severe hypoglycemia
Time frame: baseline
To evaluate the prevalence of post-traumatic stress disorder (PTSD). This PTSD is related to diabetes diagnosis and its initial management.
Score (\>44) measured on the Posttraumatic Stress Disorder Checklist Scale (PCL-S). The patient will complete the questionnaire once to evaluate PTSD related to both diabete diagnosis and its initial management.
Time frame: baseline
To evaluate the prevalence of post-traumatic stress disorder (PTSD) related to severe hypoglycemia.
Score (\>44) measured on the Posttraumatic Stress Disorder Checklist Scale (PCL-S) for severe hypoglycemia
Time frame: baseline
To evaluate the prevalence of post-traumatic stress disorder (PTSD). This PTSD is related to at least one of the following reasons : - severe hypoglycemia - diabetes diagnosis and its initial management.
Score (\>44) measured on the Posttraumatic Stress Disorder Checklist Scale (PCL-S). The patient will complete the questionnaire once to evaluate PTSD related to severe hypoglycemia and/or diabetes diagnosis and its initial management
Time frame: baseline
To evaluate the prevalence of anxiety-depressive disorder in adults with type 1 diabetes
Score (from 0 to 42 ) measured on the Hospital Anxiety and Depression Scale (HADS) Total scores can be categorized into five levels: * HADS score of 7 or less = no symptoms, * HADS score of 8 to 10 = doubtful symptomatology, * HADS score of 11 or more = definite symptomatology.
Time frame: baseline
To demonstrate the presence of anxiety-depressive disorder related to PTSD
Rate of patients with anxiety depressive disorder associated with PTSD
Time frame: baseline
To evaluate whether there is a correlation between PTSD and the patient participation to a therapeutic education program
Percentage of patients with PTSD (PCL-S \> 44) between groups of patients participating or not in a therapeutic education program (Functional Insulin Therapy or multidisciplinary education in day hospital or hospitalization)
Time frame: baseline
Plan to share: No — The participants of this study did not give written consent for their data to be shared publicly, so due to the sensitive nature of the research supporting data is not available
No publications or documents are linked to this record.
Ran from Nov 2022 to primary completion in Feb 2024, 14 months.
Of 249 non-industry observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 78. This study's 14 months is below that.
Counting every sponsor, half of 299 studies reached it within 30 months; a quarter within 12 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital St. Joseph, Marseille, France